


Amendments to the Claims:

1-8. CANCELLED.

9. (Currently Amended) The compound of Claim ~~[[1]]~~10, wherein  $R_5$  is OH,  $R_4$  is hydrogen or halogen,  $R_2$  is  $OCH_3$ ,  $NH_2$ , or  $NHCOR_{13}$ , and  $R_1$  and  $R_3$  are halogen.

10. (Currently Amended) A compound having the structure: ~~The compound of Claim 1, having the structure:~~



wherein:

$R_1$  and  $R_3$  are independently selected from the group consisting of hydrogen, halogen, alkyl, aryl alkyl,  $CF_3$ , and  $OCH_3$ ;

$R_2$  is selected from the group consisting of hydrogen, halogen, OH,  $OCH_3$ ,  $OCH_2COOH$ , C(O)-aryl, NCS,  $NH_2$ ,  $N_3$ ,  $NHR_8$ ,  $NHCH_2COOH$ ,  $NHCOR_{13}$ ,  $NHCONHR_{13}$ , and  $NHCOSR_{13}$ ;

$R_4$  and  $R_5$  are each independently selected from the group consisting of hydrogen, OH, and halogen;

$R_6$  and  $R_7$  are each independently selected from the group consisting of hydrogen and halogen;

R<sub>8</sub> is selected from the group consisting of hydrogen, lower alkyl of from 1 to about 8 carbons, halogen, OCH<sub>3</sub>, and CF<sub>3</sub>; and


R<sub>13</sub> is selected from the group consisting of hydrogen, lower alkyl of from 1 to about 8 carbons, phenyl, halogen, OCH<sub>3</sub>, CF<sub>3</sub>, and -CH<sub>2</sub>R', wherein R' is halogen;

wherein no more than one of R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> is OCH<sub>3</sub> or hydrogen and one, but not both, of R<sub>4</sub> and R<sub>5</sub> is OH;

or a pharmaceutically acceptable salt thereof.

11. (Original) The compound of Claim 10, wherein R<sub>4</sub> is OH and R<sub>5</sub> is hydrogen or halogen.
12. (Original) The compound of Claim 10, wherein R<sub>5</sub> is OH and R<sub>4</sub> is hydrogen or halogen.
13. (Original) The compound of Claim 10, wherein R<sub>6</sub> and R<sub>7</sub> are each halogen.
14. (Original) The compound of Claim 10, wherein R<sub>6</sub> and R<sub>7</sub> are each hydrogen.
15. (Original) The compound of Claim 10, wherein R<sub>2</sub> is OCH<sub>3</sub>, NH<sub>2</sub>, or NHCOR<sub>13</sub>.
16. (Original) The compound of Claim 10, wherein R<sub>1</sub> and R<sub>3</sub> are halogen.
17. (Original) The compound of Claim 10, wherein R<sub>1</sub> is halogen, R<sub>2</sub> is OCH<sub>3</sub> or NH<sub>2</sub>, and R<sub>3</sub> is hydrogen.
- 18-25. CANCELLED
26. (Currently Amended) The pharmaceutical composition of Claim ~~[[18]]~~27, wherein R<sub>5</sub> is OH, R<sub>4</sub> is hydrogen or halogen, R<sub>2</sub> is OCH<sub>3</sub>, NH<sub>2</sub>, or NHCOR<sub>13</sub>, and R<sub>1</sub> and R<sub>3</sub> are halogen.

27. (Currently Amended) A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and at least one compound having the structure: ~~The pharmaceutical composition of Claim 18, wherein said compound has the structure:~~



wherein:

R<sub>1</sub> and R<sub>3</sub> are independently selected from the group consisting of hydrogen, halogen, alkyl, aryl alkyl, CF<sub>3</sub>, and OCH<sub>3</sub>;

R<sub>2</sub> is selected from the group consisting of hydrogen, halogen, OH, OCH<sub>3</sub>, OCH<sub>2</sub>COOH, C(O)-aryl, NCS, NH<sub>2</sub>, N<sub>3</sub>, NHR<sub>8</sub>, NHCH<sub>2</sub>COOH, NHCOR<sub>13</sub>, NHCONHR<sub>13</sub>, and NHCOSR<sub>13</sub>;

R<sub>4</sub> and R<sub>5</sub> are each independently selected from the group consisting of hydrogen, OH, and halogen;

R<sub>6</sub> and R<sub>7</sub> are each independently selected from the group consisting of hydrogen and halogen;

R<sub>8</sub> is selected from the group consisting of hydrogen, lower alkyl of from 1 to about 8 carbons, halogen, OCH<sub>3</sub>, and CF<sub>3</sub>; and

R<sub>13</sub> is selected from the group consisting of hydrogen, lower alkyl of from 1 to about 8 carbons, phenyl, halogen, OCH<sub>3</sub>, CF<sub>3</sub>, and -CH<sub>2</sub>R', wherein R' is halogen;

wherein no more than one of R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> is OCH<sub>3</sub> or hydrogen and one, but not both, of R<sub>4</sub> and R<sub>5</sub> is OH;

or a pharmaceutically acceptable salt thereof.

28. (Original) The pharmaceutical composition of Claim 27, wherein  $R_4$  is OH and  $R_5$  is hydrogen or halogen.

29. (Original) The pharmaceutical composition of Claim 27, wherein  $R_5$  is OH and  $R_4$  is hydrogen or halogen.

30. (Original) The pharmaceutical composition of Claim 27, wherein  $R_6$  and  $R_7$  are each halogen.

31. (Original) The pharmaceutical composition of Claim 27, wherein  $R_6$  and  $R_7$  are each hydrogen.

32. (Original) The pharmaceutical composition of Claim 27, wherein  $R_2$  is  $OCH_3$ ,  $NH_2$ , or  $NHCOR_{13}$ .

33. (Original) The pharmaceutical composition of Claim 27, wherein  $R_1$  and  $R_3$  are halogen.


34. (Original) The pharmaceutical composition of Claim 27, wherein  $R_1$  is halogen,  $R_2$  is  $OCH_3$  or  $NH_2$ , and  $R_3$  is hydrogen.

35-42. CANCELLED

43. (Currently Amended) The method of Claim ~~[[35]]~~44, wherein  $R_5$  is OH,  $R_4$  is hydrogen or halogen,  $R_2$  is  $OCH_3$ ,  $NH_2$ , or  $NHCOR_{13}$ , and  $R_1$  and  $R_3$  are halogen.

44. (Currently Amended) A method of stimulating, regulating or modulating metabolism of fats in adipose tissue in animals, comprising administering an effective amount of at least one

compound having the structure: ~~The method of Claim 35, wherein the compound has the structure:~~



wherein:

R<sub>1</sub> and R<sub>3</sub> are independently selected from the group consisting of hydrogen, halogen, alkyl, aryl alkyl, CF<sub>3</sub>, and OCH<sub>3</sub>;

R<sub>2</sub> is selected from the group consisting of hydrogen, halogen, OH, OCH<sub>3</sub>, OCH<sub>2</sub>COOH, C(O)-aryl, NCS, NH<sub>2</sub>, N<sub>3</sub>, NHR<sub>8</sub>, NHCH<sub>2</sub>COOH, NHCOR<sub>13</sub>, NHCONHR<sub>13</sub>, and NHCOSR<sub>13</sub>;

R<sub>4</sub> and R<sub>5</sub> are each independently selected from the group consisting of hydrogen, OH, and halogen;

R<sub>6</sub> and R<sub>7</sub> are each independently selected from the group consisting of hydrogen and halogen;

R<sub>8</sub> is selected from the group consisting of hydrogen, lower alkyl of from 1 to about 8 carbons, halogen, OCH<sub>3</sub>, and CF<sub>3</sub>; and

R<sub>13</sub> is selected from the group consisting of hydrogen, lower alkyl of from 1 to about 8 carbons, phenyl, halogen, OCH<sub>3</sub>, CF<sub>3</sub>, and -CH<sub>2</sub>R', wherein R' is halogen;

wherein no more than one of R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> is OCH<sub>3</sub> or hydrogen and one, but not both, of R<sub>4</sub> and R<sub>5</sub> is OH;

or a pharmaceutically acceptable salt thereof.

45. (Original) The method of Claim 44, wherein  $R_4$  is OH and  $R_5$  is hydrogen or halogen.
46. (Original) The method of Claim 44, wherein  $R_5$  is OH and  $R_4$  is hydrogen or halogen.
47. (Original) The method of Claim 44, wherein  $R_6$  and  $R_7$  are each halogen.
48. (Original) The method of Claim 44, wherein  $R_6$  and  $R_7$  are each hydrogen.
49. (Original) The method of Claim 44, wherein  $R_2$  is  $OCH_3$ ,  $NH_2$ , or  $NHCOR_{13}$ .
50. (Original) The method of Claim 44, wherein  $R_1$  and  $R_3$  are halogen.
51. (Original) The method of Claim 44, wherein  $R_1$  is halogen,  $R_2$  is  $OCH_3$  or  $NH_2$ , and  $R_3$  is hydrogen.
52. (Currently Amended) The method of Claim ~~[[35]]~~44, wherein the compound is administered with at least one pharmaceutically acceptable carrier.